Longitudinal Assessment of Cardiac Function Following Multisystem Inflammatory Syndrome in Children Associated with

Nikkan Das1, Rachel Hill2, Mira Trivedi2

  • 1UPMC Children's Hospital of Pittsburgh, 4401 Penn Ave, Pittsburgh, PA, 15224, USA. dasn2@upmc.edu.

Pediatric Cardiology
|July 21, 2022
PubMed

Insights

Multisystem inflammatory syndrome in children (MIS-C) often involves heart issues. While ejection fraction typically recovers, abnormal global longitudinal strain persists in some, indicating potential ongoing subclinical dysfunction.

Area of Science:

  • Pediatric Cardiology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Multisystem inflammatory syndrome in children (MIS-C) following COVID-19 frequently presents with cardiac complications.
  • Myocardial dysfunction, evidenced by reduced ejection fraction and abnormal strain, is common during acute MIS-C.
  • Longitudinal data on cardiac outcomes in pediatric MIS-C patients remain limited.

Purpose of the Study:

  • To characterize the temporal evolution of cardiac findings in children diagnosed with MIS-C.
  • To assess cardiac function and deformation from acute illness through a minimum of 2-month follow-up.
  • To identify predictors of cardiac dysfunction and recovery patterns in pediatric MIS-C.

Main Methods:

  • Retrospective review of 36 pediatric patients with MIS-C admitted between April 2020 and September 2021.
  • Analysis of echocardiographic data, including left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS).
  • Cardiac assessments were performed at initial presentation, discharge, 2-4 week, and ≥2-month follow-up visits.

Main Results:

  • At presentation, 42% of MIS-C patients had reduced LVEF (<55%), and 44% of those with GLS measured had abnormal strain (< -18%).
  • Among patients with normal LVEF at presentation, 22% exhibited abnormal GLS, suggesting subclinical myocardial impairment.
  • While 90% of patients with initially reduced LVEF showed normalization by discharge, 21% had persistently abnormal GLS at 2-month follow-up.

Conclusions:

  • Myocardial systolic dysfunction and impaired deformation are prevalent in pediatric MIS-C at initial presentation.
  • Although LVEF generally recovers by 2 months, persistent abnormalities in GLS suggest ongoing subclinical cardiac dysfunction.
  • The study indicates a generally optimistic prognosis for cardiac recovery in MIS-C, but longitudinal monitoring is essential.

Related Concept Videos

Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
20
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
49
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
19
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
25
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
14